Medical News

RSS

Endosense raises USD 36 million in Series B financing

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

1 Sep 2009

Dr. Raman Bedi to exclusively represent Oragenics' oral care products

Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company’s award-winning line of oral care products to the Middle East.

1 Sep 2009

COCA to conduct meeting on ovarian cancer awareness

The Colorado Ovarian Cancer Alliance (COCA) “March on the Capitol,” on Friday, Sept. 4, noon, features speakers Lt. Gov. Barbara O’Brien, Congresswoman Diana DeGette and Dr. Daniel Donato, gynecological oncologist, Rocky Mountain Cancer Centers.

1 Sep 2009

Ascent's remanufacturing programs help hospital partners save $82 million

Ascent Healthcare Solutions, a leader in delivering healthcare resource sustainability, today announced that its hospital partners saved an astounding $82 million in unnecessary supply chain costs in the first six months of 2009 with Ascent’s reprocessing and remanufacturing programs.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

Intrexon purchases assets and operations of Avalon Pharmaceutical

Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc.

1 Sep 2009

CPRIT releases five cancer research requests after receiving first funding

The Cancer Prevention and Research Institute of Texas (CPRIT) released five cancer research requests for applications (RFA) just three months after receiving its first funding. In May, 2009, the 81st Legislature appropriated $450 million dollars in bond proceeds for the next two years for CPRIT to fund cancer research and prevention grants that will expedite innovation in cancer treatment and expand cancer prevention services in the state.

1 Sep 2009

Clinical Data raises funds by selling certain assests to Intrexon Corporation

Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company’s ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.

1 Sep 2009

Medical device report provides key data, information and analysis on diagnostic imaging market

Global Markets Direct’s medical device report: “The Future of the Diagnostic Imaging Market to 2015” report provides key data, information and analysis on the global diagnostic imaging market. The report provides market landscape, competitive landscape and market trends information on six market categories including computed tomography systems, mammography equipment, MRI systems, nuclear imaging equipment, ultrasound systems and x-ray systems.

1 Sep 2009

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Bio-Matrix Scientific Group, Inc. Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property.

1 Sep 2009

BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow

BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired the CardioNow unit of Agfa HealthCare.

From Clario 1 Sep 2009

Global Health Partner utilizes existing share purchase warrants

Global Health Partner’s (STO:GHP) CEO Per Båtelson and Deputy CEO Johan Wachtmeister have utilized existing share purchase warrants and acquired 527,444 and 527,445 shares, respectively, in Global Health Partner. The warrants were issued by a number of Global Health Partner’s shareholders, mainly by Metroland BVBA, and the strike price was 75 pence, corresponding to approximately SEK 8.75.

1 Sep 2009

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Warfarin (an oral anticoagulant) therapy for patients with atrial fibrillation - the most common type of significant heart rhythm disorder - appears to be most beneficial for the oldest patients, for those who have had a prior stroke and for patients with multiple risk factors for stroke, according to a new study by Kaiser Permanente and Massachusetts General Hospital researchers.

1 Sep 2009

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Sep 2009

Frontrow's new microphone improves students' presentation and comprehension skills

Classroom sound system maker, FrontRow(TM), has released a new pass-around microphone that's designed to be easier for young students to use. With special attention to fitting childrens' small hands, this unique tool provides an increased level of comfort for all students in K-12 classrooms, while providing excellent sound quality.

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS.

1 Sep 2009

Biovail announces Phase III trial results for pimavanserin

Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.’s first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP.

1 Sep 2009

Medical News

Endosense raises USD 36 million in Series B financing

Dr. Raman Bedi to exclusively represent Oragenics' oral care products

COCA to conduct meeting on ovarian cancer awareness

Ascent's remanufacturing programs help hospital partners save $82 million

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Intrexon purchases assets and operations of Avalon Pharmaceutical

CPRIT releases five cancer research requests after receiving first funding

Clinical Data raises funds by selling certain assests to Intrexon Corporation

Medical device report provides key data, information and analysis on diagnostic imaging market

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow

Global Health Partner utilizes existing share purchase warrants

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

Frontrow's new microphone improves students' presentation and comprehension skills

Cimzia approved for treating adult patients with rheumatoid arthritis

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced

Biovail announces Phase III trial results for pimavanserin

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News